文献速递泌尿男性生殖肿瘤

高危非肌层浸润性膀胱癌患者对2个诱导疗程卡介苗治疗的应答:2期临床试验5年随访

Response to 2 Induction Courses of Bacillus Calmette-Guèrin Therapy Among Patients With High-Risk Non-Muscle-Invasive Bladder Cancer: 5-year Follow-Up of a Phase 2 Clinical Trial.
PubMed 文献 · JAMA Oncol · 2024-01-01

这项前瞻性2期试验在2015年11月至2018年6月纳入81例高危非肌层浸润性膀胱癌患者,接受12次膀胱内卡介苗诱导灌注、不做维持治疗;75例可评估者5年无复发生存率为69%(95%CI 58%-81%),癌症特异性生存率为97%(95%CI 93%-100%),每例患者卡介苗用量从27瓶降至12瓶。

要点

  • 12次诱导灌注无维持方案使每例患者卡介苗用量从27瓶降至12瓶。
  • 75例可评估患者5年无复发生存率为69%(95%CI 58%-81%)。
  • 癌症特异性生存率为97%(95%CI 93%-100%),3例死于膀胱癌。

核心结论

  • 12次卡介苗诱导灌注不做维持治疗可减少每例患者所需瓶数,同时提供可接受的肿瘤学结局。
  • 在卡介苗短缺背景下,这一改良方案可能提供合适替代选择。

研究设计与样本

  • 前瞻性2期临床试验队列,2015年11月至2018年6月在纪念斯隆-凯特琳癌症中心入组原发或复发高危非肌层浸润性膀胱癌患者。
  • 患者接受2个诱导疗程共12次膀胱内卡介苗灌注、不做维持治疗,分析于2023年7月28日进行。
  • 81例患者同意参与,其中75例可评估长期随访;65例男性(84%)、12例女性(16%),中位年龄72岁(IQR 64-77)。

主要发现

  • 21例出现高级别复发,5年无复发生存率为69%(95%CI 58%-81%),无复发患者中位随访4.4年(IQR 3.8-5.3)。
  • 3例死于膀胱癌,癌症特异性生存率为97%(95%CI 93%-100%),存活者中位随访4.9年(IQR 4.2-5.7)。
  • 使用2个诱导疗程使每例患者卡介苗用量从27瓶降至12瓶。

关键数值与推荐

  • 复发定义为病理高级别病变,采用7.5个月界标分析评估无复发生存和癌症特异性生存。

临床怎么用

  • 作者认为,在卡介苗持续短缺背景下,12次诱导灌注不做维持治疗的改良方案可能提供合适替代选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: With the ongoing bacillus Calmette-Guèrin (BCG) shortage, alternate therapeutic options for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) are needed. OBJECTIVE: To report the 5-year outcomes of a cohort from a prospective phase 2 trial of patients with high-risk NMIBC who underwent 12 instillations of induction BCG without maintenance. DESIGN, SETTING, AND PARTICIPANTS: Between November 2015 and June 2018, patients at Memorial Sloan Kettering Cancer Center with primary or recurrent NMIBC (high-grade Ta, T1 tumors, with or without carcinoma in situ) were prospectively enrolled to receive 2 induction courses (12 intravesical instillations) of BCG without maintenance therapy. The analysis itself took place on July 28, 2023. MAIN OUTCOMES AND MEASURES: Recurrence-free survival (RFS) and cancer-specific survival (CSS) was assessed by landmark analysis at 7.5 months. Recurrence was defined as pathologic high-grade disease. RESULTS: Among 81 patients (65 men [84%] and 12 women [16%] with a median [IQR] age of 72 [64-77] years) who consented to participate in the study, 75 remained evaluable for long-term follow-up analysis. Twenty-one patients experienced high-grade recurrence, yielding a 5-year RFS rate of 69% (95% CI, 58%-81%), with a median (IQR) follow-up of 4.4 (3.8-5.3) years for patients without recurrence. Three patients died of bladder cancer, corresponding to a CSS rate of 97% (95% CI, 93%-100%) with a median (IQR) follow-up of 4.9 (4.2-5.7) years for survivors. Using 2 induction courses reduced the amount of BCG per patient from 27 vials to 12 vials. CONCLUSION AND RELEVANCE: Twelve induction instillations of BCG without maintenance for patients with high-risk NMIBC reduced the number of vials needed per patient while providing acceptable oncologic outcomes. Given the ongoing BCG shortage, this modified regimen may provide a suitable alternative in this setting.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Katims AB, Tallman J, Vertosick E, et al. Response to 2 Induction Courses of Bacillus Calmette-Guèrin Therapy Among Patients With High-Risk Non-Muscle-Invasive Bladder Cancer: 5-year Follow-Up of a Phase 2 Clinical Trial. JAMA Oncol. 2024. PMID: 38358761. doi:10.1001/jamaoncol.2023.6804

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。